The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · see citing works

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377 · see citing works

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · see citing works

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645 · see citing works

Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer

Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350 · see citing works

In situ immune response and mechanisms of cell damage in central nervous system of fatal cases microcephaly by Zika virus

Azevedo, R. S. S., de Sousa, J. R., Araujo, M. T. F., Martins Filho, A. J., de Alcantara, B. N., Araujo, F. M. C., Queiroz, M. G. L., Cruz, A. C. R., Vasconcelos, B. H. B., Chiang, J. O., et al. (2018) · Scientific Reports · doi:10.1038/s41598-017-17765-5 · Cited by 3,478 · see citing works

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,414 · see citing works

Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer

Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397 · see citing works

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Brahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967 · see citing works

Nivolumab in Patients with Metastatic DNA Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer (CheckMate 142): An Open-Label, Multicentre, Phase 2 Study

Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836 · see citing works

Durable Clinical Benefit with Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer

Overman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079 · see citing works

International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study

Pagès, F., Mlecnik, B., Marliot, F., Bindea, G., Ou, F.-S., Bifulco, C., Lugli, A., Zlobec, I., Rau, T. T., Berger, M. D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30789-x · Cited by 2,075 · see citing works

Cancer immunoediting and resistance to T cell-based immunotherapy

O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,759 · see citing works

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8931 · Cited by 1,477 · see citing works

Epithelial ovarian cancer: Evolution of management in the era of precision medicine

Lheureux, S., Braunstein, M., & Oza, A. M. (2019) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21559 · Cited by 1,432 · see citing works

Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers

Chalabi, M., Fanchi, L. F., Dijkstra, K. K., Van den Berg, J. G., Aalbers, A. G., Sikorska, K., Lopez-Yurda, M., Grootscholten, C., Beets, G. L., Snaebjornsson, P., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0805-8 · Cited by 1,417 · see citing works

Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer

Hamanishi, J., Mandai, M., Ikeda, T., Minami, M., Kawaguchi, A., Murayama, T., Kanai, M., Mori, Y., Matsumoto, S., Chikuma, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3397 · Cited by 1,176 · see citing works

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

Robert, C., Ribas, A., Schachter, J., Arance, A., Grob, J.-J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C. M., Lotem, M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30388-2 · Cited by 1,159 · see citing works

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

Muro, K., Chung, H. C., Shankaran, V., Geva, R., Catenacci, D. V. T., Gupta, S., Eder, J. P., Golan, T., Le, D. T., Burtness, B. A., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00175-3 · Cited by 1,117 · see citing works

Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer: KEYNOTE-164

Le, D. T., Kim, T. W., Van Cutsem, E., Geva, R., Jäger, D., Hara, H., Burge, M., O’Neil, B., Kavan, P., Yoshino, T., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02107 · Cited by 1,005 · see citing works

T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

Ott, P. A., Bang, Y.-J., Piha-Paul, S. A., Razak, A. R. A., Bennouna, J., Soria, J.-C., Rugo, H. S., Cohen, R. B., O’Neil, B. H., Mehnert, J. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.2276 · Cited by 969 · see citing works

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

Matulonis, U. A., Shapira‐Frommer, R., Santin, A. D., Lisyanskaya, A. S., Pignata, S., Vergote, I. B., Raspagliesi, F., Sonke, G. S., Birrer, M. J., Provencher, D. M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz135 · Cited by 855 · see citing works

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

Adams, S., Schmid, P., Rugo, H. S., Winer, E. P., Loirat, D., Awada, A., Cescon, D. W., Iwata, H., Campone, M., Nanda, R., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy517 · Cited by 807 · see citing works

Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer

Emens, L. A., Cruz, C., Eder, J. P., Braiteh, F., Chung, C. T., Tolaney, S. M., Kuter, I., Nanda, R., Cassier, P. A., Delord, J., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4224 · Cited by 775 · see citing works

Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study

Necchi, A., Anichini, A., Raggi, D., Briganti, A., Massa, S., Lucianò, R., Colecchia, M., Giannatempo, P., Mortarini, R., Bianchi, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.01148 · Cited by 741 · see citing works

Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study

Antonarakis, E. S., Piulats, J. M., Gross-Goupil, M., Goh, J., Ojamaa, K., Hoimes, C. J., Vaishampayan, U., Berger, R., Sezer, A., Alanko, T., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01638 · Cited by 736 · see citing works

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

Loibl, S., Untch, M., Burchardi, N., Huober, J., Sinn, B. V., Blohmer, J., Grischke, E., Furlanetto, J., Tesch, H., Hanusch, C. A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz158 · Cited by 698 · see citing works

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

Kim, Y. H., Bagot, M., Pinter‐Brown, L. C., Rook, A. H., Porcu, P., Horwitz, S. M., Whittaker, S. J., TOKURA, Y., Vermeer, M. H., Zinzani, P. L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30379-6 · Cited by 671 · see citing works

Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis

Hwang, W., Adams, S. F., Tahirović, E., Hagemann, I. S., & Coukos, G. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.09.039 · Cited by 658 · see citing works

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study

Adams, S., Loi, S., Toppmeyer, D., Cescon, D. W., Laurentiis, M. D., Nanda, R., Winer, E. P., Mukai, H., Tamura, K., Armstrong, A. C., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy518 · Cited by 632 · see citing works

Atezolizumab with or without Cobimetinib versus Regorafenib in Previously Treated Metastatic Colorectal Cancer (IMblaze370): A Multicentre, Open-Label, Phase 3, Randomised, Controlled Trial

Eng, C., Kim, T. W., Bendell, J., Argilés, G., Tebbutt, N. C., Di Bartolomeo, M., Falcone, A., Fakih, M., Kozloff, M., Segal, N. H., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30027-0 · Cited by 577 · see citing works

BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

Bockorny, B., Semenisty, V., Macarulla, T. M., Borazanci, E. H., Wolpin, B. M., Stemmer, S. M., Golan, T., Geva, R., Borad, M. J., Pedersen, K. S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0880-x · Cited by 563 · see citing works

Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation

Lutz, E. R., Wu, A. A., Bigelow, E. O., Sharma, R. B., Mo, G., Soares, K. C., Solt, S., Dorman, A., Wamwea, A., Yager, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0027 · Cited by 551 · see citing works

Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody

Lipson, E. J., Sharfman, W. H., Drake, C. G., WOLLNER, I. S., Taube, J. M., Anders, R. A., Xu, H., Yao, S., Pons, A., Chen, L., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2625 · Cited by 546 · see citing works

Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study

Domchek, S. M., Postel-Vinay, S. C., Im, S., Park, Y. H., Delord, J., Italiano, A., Alexandre, J., You, B., Bastian, S., Krebs, M., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30324-7 · Cited by 485 · see citing works

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial

Makker, V., Rasco, D., Vogelzang, N. J., Brose, M. S., Cohn, A. L., Mier, J., Di Simone, C., Hyman, D. M., Stepan, D. E., Dutcus, C. E., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30020-8 · Cited by 476 · see citing works

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer

Disis, M. L., Taylor, M. H., Kelly, K. L., Beck, J. T., Gordon, M. S., Moore, K. M., Patel, M. R., Chaves, J. M., Park, H., Mita, A. C., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.6258 · Cited by 438 · see citing works

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

Strauss, J., Heery, C. R., Schlom, J., Madan, R. A., Cao, L., Kang, Z., Lamping, E., Marté, J. L., Donahue, R. N., Grenga, I., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2653 · Cited by 406 · see citing works

Layer-by-layer biofunctionalization of nanostructured porous silicon for high-sensitivity and high-selectivity label-free affinity biosensing

Mariani, S., Robbiano, V., Strambini, L. M., Debrassi, A., Egri, G., Dähne, L., & Barillaro, G. (2018) · Nature Communications · doi:10.1038/s41467-018-07723-8 · Cited by 406 · see citing works

Differences in tumor microenvironment dictate T helper lineage polarization and response to immune checkpoint therapy

Jiao, S., Subudhi, S. K., Aparicio, A., Ge, Z., Guan, B., Miura, Y., & Sharma, P. (2019) · Cell · doi:10.1016/j.cell.2019.10.029 · Cited by 386 · see citing works

Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

Rugo, H. S., Delord, J., Im, S., Ott, P. A., Piha-Paul, S. A., Bedard, P. L., Sachdev, J. C., Tourneau, C. L., van Brummelen, E. M. J., Varga, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3452 · Cited by 378 · see citing works

Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer

Graff, J. N., Alumkal, J. J., Drake, C. G., THOMAS, G. V., Redmond, W. L., Farhad, M. E., Cetnar, J. P., Ey, F. S., Bergan, R. C., Slottke, R., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10547 · Cited by 360 · see citing works

Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer

Färkkilä, A., Gulhan, D., Casado, J., Jacobson, C. A., Nguyen, H. Q., Kochupurakkal, B. S., Maliga, Z., Yapp, C., Chen, Y., Schapiro, D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15315-8 · Cited by 302 · see citing works

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma

O’Neil, B. H., Wallmark, J. M., Lorente, D., Élez, E., Raimbourg, J., Gomez‐Roca, C., Ejadi, S., Piha-Paul, S. A., Stein, M. N., Razak, A. R. A., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189848 · Cited by 294 · see citing works

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

Jung, K. H., LoRusso, P. M., Burris, H. A., Gordon, M. S., Bang, Y., Hellmann, M. D., Cervantes, A. M. R., de Olza, M. O., Marabelle, A., Hodi, F. S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2740 · Cited by 277 · see citing works

Prostate cancer reactivates developmental epigenomic programs during metastatic progression

Pomerantz, M. M., Qiu, X., Zhu, Y., Takeda, D. Y., Pan, W., Baca, S. C., Gusev, A., Korthauer, K. D., Severson, T., Ha, G., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0664-8 · Cited by 266 · see citing works

Steps in metastasis: an updated review

Majidpoor, J., & Mortezaee, K. (2021) · Medical Oncology · doi:10.1007/s12032-020-01447-w · Cited by 266 · see citing works

Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen

Limagne, E., Euvrard, R., Thibaudin, M., Rébé, C., Dérangère, V., Chevriaux, A., Boidot, R., Végran, F., Bonnefoy, N., Vincent, J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3164 · Cited by 264 · see citing works

The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells

Lu, C., Redd, P. S., Lee, J. R., Savage, N. M., & Liu, K. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1247135 · Cited by 234 · see citing works

T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma

Hopkins, A. C., Yarchoan, M., Durham, J. N., Yusko, E. C., Rytlewski, J. A., Robins, H. S., Laheru, D. A., Le, D. T., Lutz, E. R., & Jaffee, E. M. (2018) · JCI Insight · doi:10.1172/jci.insight.122092 · Cited by 233 · see citing works

Enhancing global access to cancer medicines

Cortés, J., Pérez-García, J. M., Llombart‐Cussac, A., Curigliano, G., Saghir, N. S. E., Cardoso, F., Barrios, C. H., Wagle, S. M. S., Roman, J., Harbeck, N., et al. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21597 · Cited by 209 · see citing works

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer

Rodrigues, D. N., Rescigno, P., Liu, D., Yuan, W., Carreira, S., Lambros, M. B. K., Seed, G., Mateo, J., Riisnaes, R., Mullane, S. A., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci121924 · Cited by 204 · see citing works

M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine

Knudson, K. M., Hicks, K. C., Luo, X., Chen, J.-Q., Schlom, J., & Gameiro, S. R. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1426519 · Cited by 195 · see citing works

anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells

Liu, S., Qin, T., Liu, Z., Wang, J., Jia, Y., Feng, Y., Gao, Y., & Li, K. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2511-3 · Cited by 192 · see citing works

Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study

Mahalingam, D., Wilkinson, G., Eng, K. H., Fields, P., Raber, P. L., Moseley, J. L., Cheetham, K., Coffey, M. C., Nuovo, G. J., Kaliński, P., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2078 · Cited by 190 · see citing works

CXCL12/CXCR4 axis in the microenvironment of solid tumors: A critical mediator of metastasis

Mortezaee, K. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117534 · Cited by 180 · see citing works

Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer

Terranova-Barberio, M., Pawłowska, N., Dhawan, M., Moasser, M. M., Chien, A. J., Melisko, M., Rugo, H. S., Rahimi, R., Deal, T. R., DAUD, A. I., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17414-y · Cited by 175 · see citing works

Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors.

Hellmann, M. D., Kim, T.-W., Lee, C. B., Goh, B.-C., Miller, W. H., Oh, D.-Y., Jamal, R., Chee, C.-E., Chow, L. Q. M., Gainor, J. F., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz113 · Cited by 174 · see citing works

The prognostic value of tumour-infiltrating lymphocytes in pancreatic cancer: a systematic review and meta-analysis

Orhan, A., Vogelsang, R. P., Andersen, M. B., Madsen, M. T., Hölmich, E. R., Raskov, H., & Gögenür, I. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.03.013 · Cited by 170 · see citing works

Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial

Middleton, G., Brock, K., Savage, J. S., Mant, R., Summers, Y., Conibear, J., Shah, R. N. H., Ottensmeier, C. H. H., Shaw, P. H., Lee, S. M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30033-3 · Cited by 165 · see citing works

Stromal epigenetic alterations drive metabolic and neuroendocrine prostate cancer reprogramming

Mishra, R., Haldar, S., Placencio, V. R., Madhav, A., Rohena-Rivera, K., Agarwal, P., Duong, F. L., Angara, B., Tripathi, M., Liu, Z., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99397 · Cited by 164 · see citing works

PD-L1 Mediates Dysfunction in Activated PD-1+ NK Cells in Head and Neck Cancer Patients

Concha‐Benavente, F., Kansy, B., Moskovitz, J. M., Moy, J. D., Chandran, U. R., & Ferris, R. L. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0062 · Cited by 162 · see citing works

Immune escape: A critical hallmark in solid tumors

Mortezaee, K. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118110 · Cited by 159 · see citing works

Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer

Haffner, M. C., Güner, G., Taheri, D., Netto, G. J., Palsgrove, D. N., Zheng, Q., Guedes, L. B., Kim, K., Tsai, H. K., Esopi, D., et al. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2018.02.014 · Cited by 158 · see citing works

A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors

Doi, T., Muro, K., Ishii, H., Kato, T., Tsushima, T., Takenoyama, M., Oizumi, S., Gemmoto, K., Suna, H., Enokitani, K., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1090 · Cited by 154 · see citing works

Advances and potential pitfalls of oncolytic viruses expressing immunomodulatory transgene therapy for malignant gliomas

Zhang, Q., & Liu, F. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2696-5 · Cited by 139 · see citing works

Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers

Liu, J. F., Gordon, M. S., Veneris, J. T., Braiteh, F., Balmanoukian, A. S., Eder, J. P., Oaknin, A., Hamilton, E. P., Wang, Y., Sarkar, I., et al. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.05.021 · Cited by 134 · see citing works

NSD2 is a conserved driver of metastatic prostate cancer progression

Aytés, À., Giacobbe, A., Mitrofanova, A., Ruggero, K., Cyrta, J., Arriaga, J. M., Palomero, L., Farran-Matas, S., Rubin, M. A., Shen, M. M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07511-4 · Cited by 119 · see citing works

Super-geometric electron focusing on the hexagonal Fermi surface of PdCoO2

Bachmann, M. D., Sharpe, A. L., Barnard, A., Putzke, C. M., Koenig, M., Khim, S., Goldhaber‐Gordon, D., Mackenzie, A. P., & Moll, P. J. W. (2019) · RePEc: Research Papers in Economics · Cited by 116 · see citing works

The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis

Li, Y., He, M., Zhou, Y., Yang, C., Wei, S., Bian, X., Christopher, O., & Xie, L. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00139 · Cited by 114 · see citing works

Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance

Pernot, S., Terme, M., Radosevic‐Robin, N., Castan, F., Badoual, C., Marcheteau, E., Penault-Llorca, F. M., Bouché, O., Bennouna, J., François, É., et al. (2019) · Gastric Cancer · doi:10.1007/s10120-019-00983-3 · Cited by 114 · see citing works

A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses

Zimmer, A. S., Nichols, E. H., Cimino‐Mathews, A., Peer, C. J., Cao, L., Lee, M.-J., Kohn, E. C., Annunziata, C. M., Lipkowitz, S., Trepel, J. B., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0680-3 · Cited by 114 · see citing works

Safety of nivolumab plus low-dose ipilimumab in previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer

Morse, M. A., Overman, M. J., Hartman, L., Khoukaz, T., Brutcher, E., Lenz, H.-J., Atasoy, A., Shangguan, T., Zhao, H., & El-Rayes, B. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0129 · Cited by 112 · see citing works

Extreme rainfall events alter the trophic structure in bromeliad tanks across the Neotropics

Romero, G. Q., Marino, N. A. C., MacDonald, A. A. M., Céréghino, R., Trzcinski, M. K., Acosta-Mercado, D., Leroy, C., Corbara, B., Farjalla, V. F., Barberis, I. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17036-4 · Cited by 112 · see citing works

Cancer‐associated fibroblasts: Secretions, interactions, and therapy

Farhood, B., Najafi, M., & Mortezaee, K. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27703 · Cited by 109 · see citing works

Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer

Shah, A. N., Flaum, L., Helenowski, I., Santa-Maria, C. A., Jain, S., RADEMAKER, A. W., Nelson, V. M., Tsarwhas, D., Cristofanilli, M., & Gradishar, W. J. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000173 · Cited by 106 · see citing works

Immune system in cancer radiotherapy: Resistance mechanisms and therapy perspectives

Mortezaee, K., & Najafi, M. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103180 · Cited by 106 · see citing works

The Landscape of Immune Cells Infiltrating in Prostate Cancer

Wu, Z., Chen, H., Luo, W., Zhang, H., Li, G., Zeng, F., & Deng, F. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.517637 · Cited by 104 · see citing works

Cancer stem cell (a)symmetry & plasticity: Tumorigenesis and therapy relevance

Najafi, M., Mortezaee, K., & Ahadi, R. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.05.076 · Cited by 95 · see citing works

Enriched cancer stem cells, dense stroma, and cold immunity: Interrelated events in pancreatic cancer

Mortezaee, K. (2021) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22708 · Cited by 90 · see citing works

Extracellular‐signal‐regulated kinase/mitogen‐activated protein kinase signaling as a target for cancer therapy: an updated review

Najafi, M., Ahmadi, A., & Mortezaee, K. (2019) · Cell Biology International · doi:10.1002/cbin.11187 · Cited by 78 · see citing works

Immune-Phenotyping and Transcriptomic Profiling of Peripheral Blood Mononuclear Cells From Patients With Breast Cancer: Identification of a 3 Gene Signature Which Predicts Relapse of Triple Negative Breast Cancer

Foulds, G. A., Vadakekolathu, J. N., Abdel-Fatah, T. M. A., Nagarajan, D., Reeder, S., Johnson, C., Hood, S. P., Moseley, P. M., Chan, S. Y. T., Pockley, A. G., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02028 · Cited by 77 · see citing works

Avelumab (Anti-PD-L1) in Platinum-Resistant/Refractory Ovarian Cancer: JAVELIN Ovarian 200 Phase III Study Design

Pujade-Lauraine, É., Fujiwara, K., Dychter, S. S., Devgan, G., & Monk, B. J. (2018) · Future Oncology · doi:10.2217/fon-2018-0070 · Cited by 75 · see citing works

A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma—A Proof of Antigen Discovery Feasibility in Three Patients

Bassani‐Sternberg, M., Digklia, A., Huber, F., Wagner, D., Sempoux, C. L., Stevenson, B. J., Thierry, A., Michaux, J., Pak, H., Racle, J., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01832 · Cited by 75 · see citing works

Stromal reprogramming: A target for tumor therapy

Najafi, M., Mortezaee, K., & Majidpoor, J. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.117049 · Cited by 74 · see citing works

Mogamulizumab for relapsed adult T‐cell leukemia–lymphoma: Updated follow‐up analysis of phase I and II studies

Ishida, T., Utsunomiya, A., Jo, T., Yamamoto, K., Kato, K., Yoshida, S., Takemoto, S., Suzushima, H., Kobayashi, Y., Imaizumi, Y., et al. (2017) · Cancer Science · doi:10.1111/cas.13343 · Cited by 71 · see citing works

Mogamulizumab <i>versus</i> investigator’s choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma

Phillips, A. A., Fields, P. A., Hermine, O., Ramos, J. C., Beltran, B. E., Pereira, J., Wandroo, F., Feldman, T., Taylor, G. P., Sawas, A., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.205096 · Cited by 70 · see citing works

Hypoxia induces core-to-edge transition of progressive tumoral cells: A critical review on differential yet corroborative roles for HIF-1α and HIF-2α

Mortezaee, K. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.117145 · Cited by 63 · see citing works

Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer

Redman, J. M., Steinberg, S. M., & Gulley, J. L. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0409-8 · Cited by 60 · see citing works

Adoptive transfer of natural killer cells in combination with chemotherapy improves outcomes of patients with locally advanced colon carcinoma

Li, L., Li, W., Wang, C., Xu, Y., Wang, Y., Niu, C. S., Zhang, X., Li, M., Tian, H., Cheng, Y., et al. (2017) · Cytotherapy · doi:10.1016/j.jcyt.2017.09.009 · Cited by 60 · see citing works

The Reversal of Immune Exclusion Mediated by Tadalafil and an Anti-tumor Vaccine Also Induces PDL1 Upregulation in Recurrent Head and Neck Squamous Cell Carcinoma: Interim Analysis of a Phase I Clinical Trial

Weed, D. T., Zilio, S., dos Reis, I. M., Sargi, Z., Abouyared, M., Gomez-Fernandez, C. R., Civantos, F., Rodriguez, C. P., & Serafini, P. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01206 · Cited by 59 · see citing works

Comparative Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Advanced Cancer: A Systematic Review and Meta-Analysis

Yang, Y., Jin, G., Pang, Y., Huang, Y., Wang, W., Zhang, H., Tuo, G., Wu, P., Wang, Z., & Zhu, Z. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00040 · Cited by 57 · see citing works

Analysis of expression of the PD-1/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors

Sampedro-Nuñez, M. A., Serrano-Somavilla, A., Adrados, M., Cameselle‐Teijeiro, J., Blanco-Carrera, C., Cabezas-Agrícola, J. M., Martínez‐Hernández, R., Martín‐Pérez, E., de Nova, J. L. M., Díaz, J. Á., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-36129-1 · Cited by 56 · see citing works

A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer

Ross, A. E., Hurley, P. J., Tran, P. T., Rowe, S. P., Benzon, B., Neal, T. O., Chapman, C. G., Harb, R., Milman, Y., Trock, B. J., et al. (2019) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-019-0176-8 · Cited by 55 · see citing works

Prognostic effect of programmed death-ligand 1 (PD-L1) in ovarian cancer: a systematic review, meta-analysis and bioinformatics study

Wang, L. (2019) · Journal of Ovarian Research · doi:10.1186/s13048-019-0512-6 · Cited by 50 · see citing works

Pembrolizumab in patients (pts) with PD-L1–positive (PD-L1+) advanced ovarian cancer: Updated analysis of KEYNOTE-028.

Varga, A., Piha-Paul, S. A., Ott, P. A., Mehnert, J. M., Berton-Rigaud, D., Morosky, A., Zhao, G. Q., Rangwala, R. A., & Matei, D. E. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.5513 · Cited by 49 · see citing works

The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis

Chen, J., Li, S., Yao, Q., Du, N., Fu, X., Lou, Y., Wang, M., Mao, F., Mao, D., Khadaroo, P. A., et al. (2020) · World Journal of Surgical Oncology · doi:10.1186/s12957-020-01933-5 · Cited by 47 · see citing works

Redox tolerance and metabolic reprogramming in solid tumors

Mortezaee, K. (2020) · Cell Biology International · doi:10.1002/cbin.11506 · Cited by 47 · see citing works

Tumor cryoablation in combination with natural killer cells therapy and Herceptin in patients with HER2-overexpressing recurrent breast cancer

Liang, S., Niu, L., Xu, K., Wang, X., Liang, Y., Zhang, M., Chen, J., & Lin, M. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.10.003 · Cited by 42 · see citing works

Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE‐100

Nishio, S., Matsumoto, K., Takehara, K., Kawamura, N., Hasegawa, K., Takeshima, N., Aoki, D., Kamiura, S., Arakawa, A., Kondo, E., et al. (2020) · Cancer Science · doi:10.1111/cas.14340 · Cited by 40 · see citing works

Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer

Shindo, Y., Hazama, S., Suzuki, N., Iguchi, H., Uesugi, K., Tanaka, H., Aruga, A., Hatori, T., Ishizaki, H., Umeda, Y., et al. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0509-1 · Cited by 36 · see citing works

Interval breast cancer is associated with other types of tumors

Graßmann, F., He, W., Eriksson, M., Gabrielson, M., Hall, P. N., & Czene, K. (2019) · Nature Communications · doi:10.1038/s41467-019-12652-1 · Cited by 36 · see citing works

Differential gene expression in growth factors, epithelial mesenchymal transition and chemotaxis in the diffuse type compared with the intestinal type of gastric cancer

Perrot‐Applanat, M., Vacher, S., Pimpie, C., Chemlali, W., Derieux, S., Pocard, M. D., & Bièche, I. (2019) · Oncology Letters · doi:10.3892/ol.2019.10392 · Cited by 35 · see citing works

Understanding and Targeting Natural Killer Cell-Cancer-Associated Fibroblast Interactions in Pancreatic Ductal Adenocarcinoma

Malchiodi, Z. X., & Weiner, L. M. (2021) · Cancers · doi:10.3390/cancers13030405 · Cited by 34 · see citing works

Peripheral natural killer cell activity is associated with poor clinical outcomes in pancreatic ductal adenocarcinoma

Lee, H. S., Leem, G., Kang, H., Jo, J. H., Chung, M. J., Jang, S. J., Yoon, D. H., Park, J. Y., Park, S. W., Song, S. Y., et al. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15265 · Cited by 34 · see citing works

Targeting disseminated estrogen-receptor-positive breast cancer cells in bone marrow

Buschhaus, J. M., Humphries, B. A., Eckley, S. S., Robison, T. H., Cutter, A. C., Rajendran, S., Haley, H. R., Bevoor, A. S., Luker, K. E., & Luker, G. D. (2020) · Oncogene · doi:10.1038/s41388-020-01391-z · Cited by 33 · see citing works

Intraperitoneal infusion of ex vivo-cultured allogeneic NK cells in recurrent ovarian carcinoma patients (a phase I study)

Evert, J. S. H., Bekkers, R. L. M., Ottevanger, N. P. B., Schaap, N. P., Hobo, W. A., Jansen, J. H., Massuger, L. F. A. G., & Dolstra, H. (2019) · Medicine · doi:10.1097/md.0000000000014290 · Cited by 30 · see citing works

Prognostic significance of programmed cell death ligand 1 expression in patients with ovarian carcinoma

Huang, L., Deng, X., Chang, F., Wu, X., Wu, Y., & Diao, Q. (2018) · Medicine · doi:10.1097/md.0000000000012858 · Cited by 28 · see citing works

Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis

Guo, X., Li, W., Hu, J., Zhu, E. C., & Su, Q. (2020) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-02903-2 · Cited by 28 · see citing works

CXCL12-CXCL4 heterodimerization prevents CXCL12-driven breast cancer cell migration

Nguyen, K. T. P., Druhan, L. J., Avalos, B. R., Zhai, L., Rauova, L., Nesmelova, I. V., & Dréau, D. (2019) · Cellular Signalling · doi:10.1016/j.cellsig.2019.109488 · Cited by 25 · see citing works

The significance and therapeutic potential of PD-1 and its ligands in ovarian cancer: A systematic review

Zhu, X., & Lang, J. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.04.002 · Cited by 23 · see citing works

A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D

Lee, J., Kim, J., Lim, M. C., Kim, S., Kim, H. S., Choi, C. H., Yi, J. Y., Park, S., Kim, B., & on behalf of KGOG investigators (2019) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2019.30.e112 · Cited by 23 · see citing works

Laparoscopic Surgery Versus Open Surgery for Colorectal Cancer: Impacts on Natural Killer Cells

Shi, L., Guo, H., Zheng, Z., Liu, J., Jiang, Y., & Su, Y. (2020) · Cancer Control · doi:10.1177/1073274820906811 · Cited by 19 · see citing works

The immunomodulatory effects of Candida albicans isolated from the normal gastrointestinal microbiome of the elderly on colorectal cancer

Shams, K., Larypoor, M., & Salimian, J. (2021) · Medical Oncology · doi:10.1007/s12032-021-01591-x · Cited by 18 · see citing works

Abstract CT075: Phase I evaluation of M7824, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus (HPV)-associated malignancies

Strauss, J., Gatti-Mays, M. E., Cho, B., Salas, S., McClay, E. F., Redman, J. M., Sater, H. A., Donahue, R. N., Lamping, E., Burmeister, A., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-ct075 · Cited by 16 · see citing works

Influence of Interferon-Alpha Combined with Chemo (Radio) Therapy on Immunological Parameters in Pancreatic Adenocarcinoma

Karakhanova, S., Mosl, B., Harig, S., von Ahn, K., Fritz, J., Schmidt, J., Jäger, D., Werner, J., & Bazhin, A. V. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15034104 · Cited by 16 · see citing works

Clinical factors to predict outcome following mogamulizumab in adult T-cell leukemia-lymphoma

Nakashima, J., Imaizumi, Y., Taniguchi, H., Ando, K., Iwanaga, M., Itonaga, H., Sato, S., Sawayama, Y., Hata, T., Yoshida, S., et al. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2509-0 · Cited by 15 · see citing works

The Risk Ratio of Immune-Related Colitis, Hepatitis, and Pancreatitis in Patients With Solid Tumors Caused by PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis

Tian, Y., Zhang, Z., Yang, X., Li, D., Zhang, L., Li, Z., Zhang, S., Mao, Y., Jin, C., & Zhao, Y. D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00261 · Cited by 12 · see citing works

Modulation of Premetastatic Niche by the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Localized High-Risk Prostate Cancer Followed by Radical Prostatectomy: A Phase II Randomized Trial

Maughan, B. L., Pal, S. K., Gill, D. M., Boucher, K. M., Martin, C., Salgia, M. M., Nussenzveig, R. H., Liu, T., Hawks, J., Batten, J. A., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0652 · Cited by 12 · see citing works

Extracellular vesicles as tools and targets in therapy for diseases

Kumar, M. A., Baba, S. K., Sadida, H. Q., Al-Marzooqi, S. K., Jerobin, J., Altemani, F. H., Algehainy, N. A., Alanazi, M. A., Abou‐Samra, A., Kumar, R., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01735-1 · Cited by 1,447 · see citing works

Angiogenic signaling pathways and anti-angiogenic therapy for cancer

Liu, Z., Chen, H., Zheng, L., Sun, L., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,387 · see citing works

Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments

Xu, J., Ding, L., Mei, J., Hu, Y., Kong, X., Dai, S., Bu, T., Xiao, Q., & Ding, K. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02325-5 · Cited by 356 · see citing works

Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade

Pang, K., Shi, Z., Wei, L., Yang, D. F., Ma, Y.-Y., Wang, W., Wang, G.-Y., Cao, M.-Y., Dong, J., Chen, Y.-A., et al. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100907 · Cited by 265 · see citing works

Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired

Marei, H. E. S., Hasan, A., Pozzoli, G., & Cenciarelli, C. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02902-0 · Cited by 257 · see citing works

Extracellular vesicles in ovarian cancer chemoresistance, metastasis, and immune evasion

Tian, W., Lei, N., Zhou, J., Chen, M., Guo, R., Qin, B., Li, Y., & Chang, L. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04510-8 · Cited by 160 · see citing works

Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial

Antonarakis, E. S., Park, S. H., Goh, J. C. H., Shin, S. J., Lee, J., Mehra, N., McDermott, R., Sala‐González, N., Fong, P. C. C., Greil, R., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00233 · Cited by 150 · see citing works

The current knowledge concerning solid cancer and therapy

Najafi, M., Majidpoor, J., Toolee, H., & Mortezaee, K. (2021) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22900 · Cited by 131 · see citing works

The impact of hypoxia on immune state in cancer

Mortezaee, K., & Majidpoor, J. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.120057 · Cited by 100 · see citing works

Effective Combinations of Immunotherapy and Radiotherapy for Cancer Treatment

Yu, S., Wang, Y., He, P., Shao, B., Liu, F., Xiang, Z., Yang, T., Zeng, Y., He, T., Ma, J., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.809304 · Cited by 94 · see citing works

The interactions of paclitaxel with tumour microenvironment

Yu, D., Lou, Z., Ma, F.-Y., & Najafi, M. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108555 · Cited by 88 · see citing works

IL-2 based cancer immunotherapies: an evolving paradigm

Rokade, S., Mehta-Damani, A., Oft, M., & Emmerich, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1433989 · Cited by 87 · see citing works

Anti-PD-1/PD-L1 therapy for colorectal cancer: Clinical implications and future considerations

Chen, X., Chen, L., Peng, X., Deng, L., Wang, Y., Li, J.-J., Guo, D., & Niu, X. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101851 · Cited by 80 · see citing works

Myeloid-derived suppressor cells in cancer immunotherapy-clinical perspectives

Mortezaee, K. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119627 · Cited by 73 · see citing works

Prostate cancer immunotherapy: a review of recent advancements with novel treatment methods and efficacy.

Wang, I., Song, L., Wang, B. Y., Kalebasty, A. R., Uchio, E., & Zi, X. (2022) · PubMed Central · Cited by 73 · see citing works

Chemotherapy‐Enabled Colorectal Cancer Immunotherapy of Self‐Delivery Nano‐PROTACs by Inhibiting Tumor Glycolysis and Avoiding Adaptive Immune Resistance

Zhao, L.-P., Zheng, R.-R., Rao, X., Huang, C.-Y., Zhou, H., Yu, X.-Y., Jiang, X.-Y., & Li, S.-Y. (2024) · Advancement of science · doi:10.1002/advs.202309204 · Cited by 80 · see citing works

Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors

Pawłowska, A., Rekowska, A. K., Kuryło, W., Pańczyszyn, A., Kotarski, J., & Wertel, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310859 · Cited by 66 · see citing works

The programmed site-specific delivery of LY3200882 and PD-L1 siRNA boosts immunotherapy for triple-negative breast cancer by remodeling tumor microenvironment

Zhang, P., Qin, C., Liu, N., Zhou, X., Chu, X., Lv, F., Gu, Y., Yin, L., Liu, J., Zhou, J., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121518 · Cited by 63 · see citing works

Sialylated glycoproteins suppress immune cell killing by binding to Siglec-7 and Siglec-9 in prostate cancer

Wen, R. M., Stark, J. C., Marti, G. E., Fan, Z., Lyu, A., Garcia-Marques, F. J., Zhang, X., Riley, N. M., Totten, S. M., Bermudez, A., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci180282 · Cited by 61 · see citing works

Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy

Rouzbahani, E., Majidpoor, J., Najafi, S., & Mortezaee, K. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113906 · Cited by 62 · see citing works

Interleukin-2 therapy of cancer-clinical perspectives

Majidpoor, J., & Mortezaee, K. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107836 · Cited by 59 · see citing works

Roles for macrophage-polarizing interleukins in cancer immunity and immunotherapy

Mortezaee, K., & Majidpoor, J. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00667-8 · Cited by 46 · see citing works

Tumor-associated Macrophages (TAMs) in Cancer Resistance; Modulation by Natural Products

Lafta, H. A., AbdulHussein, A. H., Al-Shalah, S. A. J., Alnassar, Y. S., Mohammed, N. M., Akram, S. M., Qasim, M. T., & Najafi, M. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666230201145909 · Cited by 61 · see citing works

Recent progress, perspectives, and issues of engineered PD-L1 regulation nano-system to better cure tumor: A review

Zhou, Z., Wang, H., Li, J., Jiang, X., Li, Z., & Shen, J. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.127911 · Cited by 54 · see citing works

Integrated Machine Learning and Single-Sample Gene Set Enrichment Analysis Identifies a TGF-Beta Signaling Pathway Derived Score in Headneck Squamous Cell Carcinoma

Wu, S., Lv, X., Li, Y., Gao, X., Ma, Z., Fu, X., & Li, Y. (2022) · Journal of Oncology · doi:10.1155/2022/3140263 · Cited by 52 · see citing works

Normalization in tumor ecosystem: Opportunities and challenges

Mortezaee, K. (2021) · Cell Biology International · doi:10.1002/cbin.11655 · Cited by 49 · see citing works

Checkpoint inhibitor/interleukin‐based combination therapy of cancer

Mortezaee, K., & Majidpoor, J. (2022) · Cancer Medicine · doi:10.1002/cam4.4659 · Cited by 45 · see citing works

The role of TGF-β in the tumor microenvironment of pancreatic cancer

Luo, Q., Hu, Z., Zhao, H., Fan, Y., Tu, X., Wang, Y., & Liu, X. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.10.019 · Cited by 44 · see citing works

The impact of hypoxia on tumor-mediated bypassing anti-PD-(L)1 therapy

Mortezaee, K., Majidpoor, J., & Kharazinejad, E. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114646 · Cited by 45 · see citing works

The role of matrix stiffness in breast cancer progression: a review

Xu, R., Yin, P., Wei, J., & Ding, Q. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1284926 · Cited by 44 · see citing works

Propranolol reduces IFN-γ driven PD-L1 immunosuppression and improves anti-tumour immunity in ovarian cancer

Falcinelli, M., Alhity, G., Baron, S., Mampay, M., Allen, M. C., Samuels, M. E., Jones, W., Cilibrasi, C., Flaherty, R. L., Giamas, G., et al. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.02.011 · Cited by 43 · see citing works

Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment

Sun, B. L. (2021) · The Prostate · doi:10.1002/pros.24213 · Cited by 43 · see citing works

Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer

Zhang, Y., Cui, Q., Xu, M., Liu, D., Yao, S., & Chen, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.901772 · Cited by 43 · see citing works

Key promoters of tumor hallmarks

Mortezaee, K., & Majidpoor, J. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-02074-9 · Cited by 41 · see citing works

Resveratrol in Cancer Therapy: From Stimulation of Genomic Stability to Adjuvant Cancer Therapy: A Comprehensive Review

Amini, P., Moazamiyanfar, R., Dakkali, M. S., Khani, A., Jafarzadeh, E., Moloudi, K., Khodamoradi, E., Johari, R., Taeb, S., & Najafi, M. (2022) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666221014152759 · Cited by 41 · see citing works

Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer

Yang, T.-L., Li, W., Huang, T., & Zhou, J. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13030526 · Cited by 41 · see citing works

Chemokines in the Landscape of Cancer Immunotherapy: How They and Their Receptors Can Be Used to Turn Cold Tumors into Hot Ones?

Karin, N. (2021) · Cancers · doi:10.3390/cancers13246317 · Cited by 40 · see citing works

Epithelial-mesenchymal transition in cancer stemness and heterogeneity: updated

Mortezaee, K., Majidpoor, J., & Kharazinejad, E. (2022) · Medical Oncology · doi:10.1007/s12032-022-01801-0 · Cited by 38 · see citing works

Nobiletin in Cancer Therapy; Mechanisms and Therapy Perspectives

Moazamiyanfar, R., Rezaei, S., Aliashrafzadeh, H., Rastegar‐Pouyani, N., Jafarzadeh, E., Moloudi, K., Khodamoradi, E., Zhaleh, M., Taeb, S., & Najafi, M. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230426115424 · Cited by 39 · see citing works

Immunotherapy of hepatocellular carcinoma: recent progress and new strategy

Li, J., Xuan, S., Dong, P., Xiang, Z., Gao, C., Li, M., Huang, L. J., & Wu, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1192506 · Cited by 38 · see citing works

The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors

Najafi, S., Majidpoor, J., & Mortezaee, K. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121138 · Cited by 37 · see citing works

CDK5 destabilizes PD-L1 via chaperon-mediated autophagy to control cancer immune surveillance in hepatocellular carcinoma

Zhang, R., Wang, J., Du, Y., Yu, Z., Wang, Y., Jiang, Y., Wu, Y., Le, T., Li, Z., Zhang, G., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007529 · Cited by 36 · see citing works

Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?

Kuske, M., Haist, M., Jung, T., Grabbe, S., & Bros, M. (2022) · Cancers · doi:10.3390/cancers14071710 · Cited by 36 · see citing works

(Im)maturity in Tumor Ecosystem

Mortezaee, K., & Majidpoor, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.813897 · Cited by 34 · see citing works

Advancements in Melanoma Treatment: A Review of PD-1 Inhibitors, T-VEC, mRNA Vaccines, and Tumor-Infiltrating Lymphocyte Therapy in an Evolving Landscape of Immunotherapy

Mehta, A., Motavaf, M., Nebo, I. D., Luyten, S., Osei-Opare, K. D., & Gru, A. A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041200 · Cited by 36 · see citing works

Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants

Macchini, M., Centonze, F., Peretti, U., Orsi, G., Militello, A. M., Valente, M. M., Cascinu, S., & Reni, M. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102262 · Cited by 33 · see citing works

VISTA immune regulatory effects in bypassing cancer immunotherapy: Updated

Mortezaee, K., Majidpoor, J., & Najafi, S. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121083 · Cited by 33 · see citing works

A pan-cancer multi-omics analysis of lactylation genes associated with tumor microenvironment and cancer development

Wu, Z., Wu, H., Dai, Y., Wang, Z., Han, H., Shen, Y., Zhang, R., & Wang, X. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27465 · Cited by 35 · see citing works

Tumor microenvironment manipulates chemoresistance in ovarian cancer (Review)

Zhang, Q., Ding, J., Wang, Y., He, L., & Xue, F. (2022) · Oncology Reports · doi:10.3892/or.2022.8313 · Cited by 33 · see citing works

Immunoregulation by resveratrol; implications for normal tissue protection and tumour suppression

Lalani, A. R., Fakhari, F., Radgoudarzi, S., Rastegar‐Pouyani, N., Moloudi, K., Khodamoradi, E., Taeb, S., & Najafi, M. (2023) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13760 · Cited by 32 · see citing works

CD8+ T Cells in SARS-CoV-2 Induced Disease and Cancer—Clinical Perspectives

Mortezaee, K., & Majidpoor, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.864298 · Cited by 34 · see citing works

Tumor Microenvironment Responsive CD8+ T Cells and Myeloid‐Derived Suppressor Cells to Trigger CD73 Inhibitor AB680‐Based Synergistic Therapy for Pancreatic Cancer

Chen, Q., Yin, H., He, J., Xie, Y., Wang, W., Xu, H., Zhang, L., Shi, C., Yu, J., Wu, W., et al. (2023) · Advanced Science · doi:10.1002/advs.202302498 · Cited by 29 · see citing works

Intelligent Biomimetic Nanoplatform for Systemic Treatment of Metastatic Triple-Negative Breast Cancer via Enhanced EGFR-Targeted Therapy and Immunotherapy

Wang, X., Zhu, X., Li, B., wei, X., Chen, Y., Zhang, Y., Wang, Y., Zhang, W., Liu, S., Liu, Z., et al. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c02925 · Cited by 29 · see citing works

Combined immunotherapy for metastatic triple-negative breast cancer based on PD-1/PD-L1 immune checkpoint blocking

He, R., Yuan, X., Chen, Z., & Zheng, Y. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109444 · Cited by 29 · see citing works

Biomarkers for predicting tumor response to PD-1 inhibitors in patients with advanced pancreatic cancer

Qiu, X., Shi, Z., Tong, F., Lu, C., Zhu, Y., Wang, Q.-L., Gu, Q., Qian, X., Meng, F., Liu, B., et al. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2178791 · Cited by 28 · see citing works

DNA damage response and PD-1/PD-L1 pathway in ovarian cancer

Zhang, T., Zheng, S., Yang, L., Li, X., Wu, J., Sun, Y., & Liu, G. (2021) · DNA repair · doi:10.1016/j.dnarep.2021.103112 · Cited by 27 · see citing works

Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study

Graff, J., Burotto, M., Fong, P. C. C., Pook, D. W., Zurawski, B., Kopp, R. M., Salinas, J., Bylow, K. A., Kramer, G., Ratta, R., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.05.007 · Cited by 31 · see citing works

Glyoxalase-1-Dependent Methylglyoxal Depletion Sustains PD-L1 Expression in Metastatic Prostate Cancer Cells: A Novel Mechanism in Cancer Immunosurveillance Escape and a Potential Novel Target to Overcome PD-L1 Blockade Resistance

Antognelli, C., Mandarano, M., Prosperi, E., Sidoni, A., & Talesa, V. N. (2021) · Cancers · doi:10.3390/cancers13122965 · Cited by 26 · see citing works

An exosome-derived lncRNA signature identified by machine learning associated with prognosis and biomarkers for immunotherapy in ovarian cancer

Cui, Y., Zhang, W., Lü, W., Feng, Y., Wu, X., Zhuo, Z., Zhang, D., & Zhang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1228235 · Cited by 26 · see citing works

Chang Wei Qing Decoction enhances the anti-tumor effect of PD-1 inhibitor therapy by regulating the immune microenvironment and gut microbiota in colorectal cancer

Wang, T., Wu, L., Wang, S., Shi, X., Liu, H., & Deng, W. (2023) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(23)60451-0 · Cited by 25 · see citing works

Regulation of pancreatic cancer therapy resistance by chemokines

Gautam, S. K., Basu, S., Aithal, A., Dwivedi, N. V., Gulati, M., & Jain, M. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.08.010 · Cited by 25 · see citing works

Huaier-induced suppression of cancer-associated fibroblasts confers immunotherapeutic sensitivity in triple-negative breast cancer

Li, C., Wang, X., Xing, L., Chen, T., Li, W., Li, X., Wang, Y., Yang, C., & Yang, Q. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.156051 · Cited by 24 · see citing works

Lipid metabolism-related gene signature predicts prognosis and depicts tumor microenvironment immune landscape in gliomas

Li, J., Zhang, S., Chen, S., Yuan, Y., Zuo, M., Li, T., Wang, Z., & Liu, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1021678 · Cited by 24 · see citing works

Immunotherapy in Prostate Cancer: State of Art and New Therapeutic Perspectives

Maselli, F. M., Giuliani, F., Laface, C., Perrone, M., Melaccio, A., Santis, P. D., Santoro, A. N., Guarini, C., Iaia, M. L., & Fedele, P. (2023) · Current Oncology · doi:10.3390/curroncol30060432 · Cited by 24 · see citing works

Dysregulated metabolism: A friend-to-foe skewer of macrophages

Mortezaee, K., & Majidpoor, J. (2022) · International Reviews of Immunology · doi:10.1080/08830185.2022.2095374 · Cited by 24 · see citing works

PD-L1 and Notch as novel biomarkers in pancreatic sarcomatoid carcinoma: a pilot study

Silvestris, N., Argentiero, A., Brunetti, O., Sonnessa, M., Colonna, F., Delcuratolo, S., Luchini, C., Scarpa, A., Lonardi, S., Nappo, F., et al. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.2011859 · Cited by 23 · see citing works

Synergistic targeting strategies for prostate cancer

Li, X., Han, Z., & Ai, J. (2025) · Nature Reviews Urology · doi:10.1038/s41585-025-01042-6 · Cited by 21 · see citing works

SChLAP1 contributes to non-small cell lung cancer cell progression and immune evasion through regulating the AUF1/PD-L1 axis

Du, Z., Niu, S., Wang, J., Wu, J., Li, S., & Yi, X. (2021) · Autoimmunity · doi:10.1080/08916934.2021.1913582 · Cited by 21 · see citing works

Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study

Bersanelli, M., Verzoni, E., Cortellini, A., Giusti, R., Calvetti, L., Ermacora, P., Napoli, M. D., Catino, A., Guadalupi, V., Guaitoli, G., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102044 · Cited by 20 · see citing works

Priming immunity via herbal components and their nanomedicines for the treatment of cancer

Li, X., Gong, C., Naeem, A., Liu, J., Yang, M., Zhang, J., & Shang, H. (2024) · Acupuncture and Herbal Medicine · doi:10.1097/hm9.0000000000000135 · Cited by 20 · see citing works

Targeting inflammatory microenvironments: overcoming therapy resistance and immunosuppression

Zhou, Y., Bai, M., Chen, L., Han, H., Hou, S., Wang, X., Fan, P., Han, S., Chen, F., Li, J., et al. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02583-z · Cited by 23 · see citing works

Tumor-Infiltrating PD-1hiCD8+-T-Cell Signature as an Effective Biomarker for Immune Checkpoint Inhibitor Therapy Response Across Multiple Cancers

Yang, Z., Deng, Y., Cheng, J., Wei, S., Luo, H., & Liu, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.695006 · Cited by 20 · see citing works

Cuproptosis-based layer-by-layer silk fibroin nanoplatform-loaded PD-L1 siRNA combining photothermal and chemodynamic therapy against metastatic breast cancer

Li, Z., Cheng, L., Xu, X. M., Jia, R., Zhu, S., Zhang, Q., Cheng, G., Wu, B., Liu, Z., Tong, X., et al. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.101298 · Cited by 19 · see citing works

A pan-cancer analysis of the oncogenic role of zinc finger protein 419 in human cancer

Zhu, W., Feng, D., Shi, X., Li, D., Wei, Q., & Yang, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1042118 · Cited by 20 · see citing works

Unveiling clinical significance and tumor immune landscape of CXCL12 in bladder cancer: Insights from multiple omics analysis

Tuo, Z., Feng, D., Jiang, Z., Bi, L., Yang, C., & Wang, Q. (2023) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2023.06.12 · Cited by 19 · see citing works

Prosaposin, tumor‐secreted protein, promotes pancreatic cancer progression by decreasing tumor‐infiltrating lymphocytes

Miyahara, Y., Takano, S., Sogawa, K., Tomizawa, S., Furukawa, K., Takayashiki, T., Kuboki, S., & Ohtsuka, M. (2022) · Cancer Science · doi:10.1111/cas.15444 · Cited by 19 · see citing works

Therapeutic challenge for immunotherapy targeting cold colorectal cancer: A narrative review

Ma, S., Li, L., Cai, H., Guo, T., & Zhang, L. (2023) · World Journal of Clinical Oncology · doi:10.5306/wjco.v14.i2.81 · Cited by 18 · see citing works

A small molecule directly targets NLRP3 to promote inflammasome activation and antitumor immunity

Liu, X., He, H., Qi, M., Jiang, Z., Lin, B., Wang, X., Wang, D., Ma, M., Jiang, W., & Zhou, R. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07578-0 · Cited by 18 · see citing works

Pheophorbide A–Mediated Photodynamic Therapy Potentiates Checkpoint Blockade Therapy of Tumor with Low PD–L1 Expression

Tong, Q., Xu, J., Wu, A., Zhang, C., Yang, A., Zhang, S., Lin, H., & Lü, W. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112513 · Cited by 18 · see citing works

Neoadjuvant checkpoint blockade in combination with Chemotherapy in patients with tripe-negative breast cancer: exploratory analysis of real-world, multicenter data

Deng, H., Wang, L., Wang, N., Zhang, K., Zhao, Y., Qiu, P., Qi, X., Zhang, D., Xu, F., & Liu, J. (2023) · BMC Cancer · doi:10.1186/s12885-023-10515-z · Cited by 18 · see citing works

TIMELESS upregulates PD-L1 expression and exerts an immunosuppressive role in breast cancer

Dong, X., Dai, H., Lin, Y., Sheng, X., Li, Y., Wang, Y., Zhang, X., Jiang, S., Yin, W., & Lu, J. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04257-6 · Cited by 18 · see citing works

Immune-related gene-based prognostic index for predicting survival and immunotherapy outcomes in colorectal carcinoma

Liang, Z., Sun, R., Tu, P., Liang, Y., Li, L., Liu, F., Bian, Y., Yin, G., Zhao, F., Jiang, M. C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.944286 · Cited by 17 · see citing works

Pathogenic Th17 cell-mediated liver fibrosis contributes to resistance to PD-L1 antibody immunotherapy in hepatocellular carcinoma

Song, M., Wang, L., Jiang, S., Liang, J., Li, W., Rao, W., Du, Q., Liu, G., Meng, H., Tang, L., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111601 · Cited by 19 · see citing works

Cellular immune states in SARS-CoV-2-induced disease

Mortezaee, K., & Majidpoor, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1016304 · Cited by 16 · see citing works

A Liquid–Liquid Phase Separation-Related Index Associate with Biochemical Recurrence and Tumor Immune Environment of Prostate Cancer Patients

You, Q., Chen, J., Wu, X., Xue, Y., Sun, J., Wei, Y., Zheng, Q., Xue, X., Chen, D., & Xu, N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065515 · Cited by 16 · see citing works

A novel immune score model predicting the prognosis and immunotherapy response of breast cancer

Lv, W., He, X., Wang, Y., Zhao, C., Dong, M., Wu, Y., & Zhang, Q. (2023) · Scientific Reports · doi:10.1038/s41598-023-31153-2 · Cited by 16 · see citing works

Senescence-associated lncRNAs indicate distinct molecular subtypes associated with prognosis and androgen response in patients with prostate cancer

Feng, D., Li, D., Wang, J., Wu, R., & Zhang, C. (2023) · Acta Materia Medica · doi:10.15212/amm-2023-0025 · Cited by 16 · see citing works

The Circular RNA circFGFR4 Facilitates Resistance to Anti-PD-1 of Triple-Negative Breast Cancer by Targeting the miR-185-5p/CXCR4 Axis

Wang, F., Lu, Q., Yu, H., & Zhang, X. (2023) · Cancer Management and Research · doi:10.2147/cmar.s411901 · Cited by 16 · see citing works

Targeting triple-negative breast cancer cells with a β1-integrin binding aptamer

Pleiko, K., Haugas, M., Parfejevs, V., Panteļejevs, T., Parisini, E., Teesalu, T., & Riekstiņa, U. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.08.015 · Cited by 16 · see citing works

Pancancer analysis uncovers an immunological role and prognostic value of the m6A reader IGF2BP2 in pancreatic cancer

Deng, H., Yao, H., Zhou, S., He, C., Huang, Y., Li, Y., Chen, H., & Shu, J. (2023) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2023.101948 · Cited by 16 · see citing works

The Crosstalk between Nerves and Cancer—A Poorly Understood Phenomenon and New Possibilities

Benzaquen, D., Lawrence, Y. R., Taussky, D., Zwahlen, D. R., Oehler, C., & Champion, A. (2024) · Cancers · doi:10.3390/cancers16101875 · Cited by 17 · see citing works

Periodontitis promotes tumor growth and immune evasion via PD-1/PD-L1

Wang, S., Nie, F., Yin, Q., Tian, H., Gong, P., Ju, J., Liu, J., Yang, P., & Yang, C. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03865-5 · Cited by 16 · see citing works

Applications of Magnetite Nanoparticles in Cancer Immunotherapies: Present Hallmarks and Future Perspectives

Song, Q., Javid, A., Zhang, G., & Li, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.701485 · Cited by 15 · see citing works

Comprehensive analysis of the immunological implication and prognostic value of CXCR4 in non-small cell lung cancer

Guo, W., Huai, Q., Zhou, B., Guo, L., Sun, L., Xue, X., Tan, F., Xue, Q., Gao, S., & He, J. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03298-y · Cited by 15 · see citing works

CD155-TIGIT Axis as a Therapeutic Target for Cancer Immunotherapy

Mu, Y., & Guan, X. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867330666230324152532 · Cited by 15 · see citing works

Programmed death ligand 1 (PD-L1) plays a vital part in DC tolerogenicity induced by IFN-γ

Švajger, U., Tešić, N., & Rožman, P. J. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107978 · Cited by 15 · see citing works

Galectin-9 and PD-L1 Antibody Blockade Combination Therapy Inhibits Tumour Progression in Pancreatic Cancer

Li, E., Xu, J., Chen, Q., Zhang, X., Xu, X., & Liang, T. (2023) · Immunotherapy · doi:10.2217/imt-2021-0075 · Cited by 16 · see citing works

Extracellular vesicle-based checkpoint regulation and immune state in cancer

Mortezaee, K., & Majidpoor, J. (2022) · Medical Oncology · doi:10.1007/s12032-022-01837-2 · Cited by 14 · see citing works

Anti‐cathepsin D immunotherapy triggers both innate and adaptive anti‐tumour immunity in breast cancer

David, T., Mallavialle, A., Faget, J., Alcaraz, L. B., Lapierre, M., du Roure, P. D., Laurent‐Matha, V., Mansouri, H., Jarlier, M., Martineau, P., et al. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16291 · Cited by 14 · see citing works

Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients

Kumar, S., Chatterjee, M., Ghosh, P., Ganguly, K. K., Basu, M., & Ghosh, M. K. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.07.024 · Cited by 132 · see citing works

Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression

Asano, Y., Kashiwagi, S., Goto, W., Takada, K., Takahashi, K., Morisaki, T., Fujita, H., Takashima, T., Tomita, S., Ohsawa, M., et al. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1458-y · Cited by 45 · see citing works

PD-L1-Positive High-Grade Triple-Negative Breast Cancer Patients Respond Better to Standard Neoadjuvant Treatment—A Retrospective Study of PD-L1 Expression in Relation to Different Clinicopathological Parameters

Stanowska, O., Kuczkiewicz‐Siemion, O., Dębowska, M., Olszewski, W. P., Jagiełło-Gruszfeld, A., Tysarowski, A., & Prochorec‐Sobieszek, M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195524 · Cited by 21 · see citing works

Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer

Chen, X., Feng, L., Huang, Y., Wu, Y., & Xie, N. (2022) · Cancers · doi:10.3390/cancers15010104 · Cited by 81 · see citing works

PD-1/PD-L1 axis importance and tumor microenvironment immune cells

Lotfinejad, P., Kazemi, T., Mokhtarzadeh, A., Shanehbandi, D., Jadidi‐Niaragh, F., Safaei, S., Asadi, M., & Baradaran, B. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118297 · Cited by 52 · see citing works